entertainment -WSS

entertainment

author：entertainment 2025-10-03 00:39:25 - browse：5

A dosage of Wegovy, a drug used for weight loss — Amanda Andrade-Rhoades/AP

U.S. regulators approved a label expansion for Novo Nordisk’s obesity drug Wegovy to tout its benefits for the heart, a move that could boost demand and insurance coverage for the already highly popular treatment.

The new label indicates that Wegovy can be used to reduce the risk of major heart complications — including heart attack, stroke, or cardiovascular-related deaths — for people with overweight or obesity and existing heart disease, Novo said in a statement Friday.

The decision was based on results of a large, five-year trial that showed Wegovy cut the risk of cardiovascular problems by 20% in that population. This is the first time a weight loss treatment has been approved to also help improve heart outcomes, the FDA said.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Adults seen as increasingly susceptible to measles

WSS

Breakthrough Alzheimer’s drugs are inaccessible in rural states

Biden warns of ‘dark winter’ during final presidental debate

Democrats decry new health bill for going easy on private equity

Mega Millions pot grows to $1.25 billion after no winner

NIH launches clinical trials and new research office for long Covid

Physician groups backed by private equity giant lobby on mergers

focus

entertainment

knowledge

State Dept. review finds Biden bears some blame for Afghanistan failures

Why patients can’t get everything they want on drug pricing

What does generative AI mean for health care? We asked experts

A new crop of companies is reshaping the health data economy

George Santos makes 1st court appearance after pleading not guilty to 13 counts

In the gardens at Boston Children's Hospital, families find sanctuary

How to save PrEP access — and even expand it

Truvian presents data for its desktop blood

What does generative AI mean for health care? We asked experts

The battle over 'scope creep' and who gets to be called 'doctor'

hotspot

The high personal cost of affirmative action for Black doctors

How doctors’ personal politics affect patients

No plane should take off without an EpiPen onboard

Micronoma's microbiome cancer diagnostic approach under fire

Wildfire pollution widens asthma inequities on Long Island

Hyundai and Kia recall nearly 92,000 vehicles and tell owners to park them outside due to fire risk

focus

focus

focus

focus